Logo
x

Search

Subscribe Now

 IgA Nephropathy

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

  • May 27, 2024
For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

  • May 23, 2024
CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy

CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy

  • April 24, 2024
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

  • April 16, 2024
Vertex to Acquire Alpine Immune Sciences for ~$4.9B

Vertex to Acquire Alpine Immune Sciences for ~$4.9B

  • April 11, 2024
Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

  • March 12, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.